Press release
APAC Metastatic HR+/HER2-Ve Breast Cancer Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight
APAC Metastatic HR+/HER2-Ve Breast Cancer Market
To Know in detail about the Metastatic HR+/HER2-Ve Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic HR+/HER2-Ve Breast Cancer Market Forecast
https://www.delveinsight.com/sample-request/metastatic-hr-positive-her2-negative-breast-cancer-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key facts of the Metastatic HR+/HER2-Ve Breast Cancer Market Report:
• The APAC Metastatic HR+/HER2-Ve Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2025, the US FDA approved DATROWAY (for unresectable or metastatic HR+, HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease) and ENHERTU (unresectable or metastatic HR+, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer that has progressed on one or more endocrine therapies in the metastatic setting.
• In January 2025, Roche announced positive topline results from the Phase III INAVO120 study investigating ITOVEBI in combination with IBRANCE and fulvestrant for people with PIK3CA-mutated HR+/HER2-, endocrine-resistant, locally advanced or metastatic breast cancer.
• In September 2024, AstraZeneca and Daiichi Sankyo have announced results from the TROPION-Breast01 Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) for breast cancer. The trial compared Dato-DXd with the investigator's selected chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.
• In June 2024, G1 Therapeutics has revealed topline results from the final overall survival (OS) analysis of its Phase III PRESERVE 2 trial, which assessed the efficacy and safety of trilaciclib given before chemotherapy (gemcitabine and carboplatin; GCb) in patients with metastatic triple-negative breast cancer (TNBC).
• In May 2024 The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to inavolisib, an investigational oral treatment, when used in combination with palbociclib (Ibrance®) and fulvestrant. This combination is intended for the treatment of adult patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
• In February 2024, Carrick Therapeutics has announced that the first patient has been treated in its Phase Ib/II clinical trial, which is assessing the combination of samuraciclib (CT7001) in women with ER-positive, HER2-negative metastatic breast cancer.
• Key Metastatic HR+/HER2-Ve Breast Cancer Companies: Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others
• Key Metastatic HR+/HER2-Ve Breast Cancer Therapies: KEYTRUDA (perbrolizumab), ARV-471 (vepdegestrant), OP1250 (palazestrant), Gedatolisib, Giredestrant (RG6171, GDC-9545), Datopotamab Deruxtecan (Dato-DXd), Camizestrant (AZD9833), LY3484356/Imlunestrant, Lasofoxifene, Capivasertib, Inavolisib, Enobosarm, DB-1303, SFX-01, Samuraciclib (CT-7001), Lerociclib, Eftilagimod Alpha (LAG-3lg/IMP321), and others
• The Metastatic HR+/HER2-Ve Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic HR+/HER2-Ve Breast Cancer pipeline products will significantly revolutionize the Metastatic HR+/HER2-Ve Breast Cancer market dynamics.
Metastatic HR+/HER2-Ve Breast Cancer Overview
Metastatic breast cancer characterized by positive hormone receptors and HER2 positivity (HR+/HER2+) represents a distinct subtype of breast cancer. Standard guidelines advise the initiation of combination treatments involving anti-HER2 therapy as the initial approach for HER2-positive metastatic breast cancer, regardless of hormone receptor status.
Get a Free sample for the Metastatic HR+/HER2-Ve Breast Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/metastatic-hr-positive-her2-negative-breast-cancer-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Metastatic HR+/HER2-Ve Breast Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2020-2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Metastatic HR+/HER2-Ve Breast Cancer Epidemiology Segmentation:
The Metastatic HR+/HER2-Ve Breast Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the APAC region is segmented into:
• Total Prevalence of Metastatic HR+/HER2-Ve Breast Cancer
• Prevalent Cases of Metastatic HR+/HER2-Ve Breast Cancer by severity
• Gender-specific Prevalence of Metastatic HR+/HER2-Ve Breast Cancer
• Diagnosed Cases of Episodic and Chronic Metastatic HR+/HER2-Ve Breast Cancer
Download the report to understand which factors are driving Metastatic HR+/HER2-Ve Breast Cancer epidemiology trends @ Metastatic HR+/HER2-Ve Breast Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/metastatic-hr-positive-her2-negative-breast-cancer-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Metastatic HR+/HER2-Ve Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic HR+/HER2-Ve Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic HR+/HER2-Ve Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Metastatic HR+/HER2-Ve Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Metastatic HR+/HER2-Ve Breast Cancer Therapies and Key Companies
• KEYTRUDA (perbrolizumab): Merck
• ARV-471 (vepdegestrant): Arvinas
• OP1250 (palazestrant): Olema Pharmaceuticals
• Gedatolisib: Celcuity
• Giredestrant (RG6171, GDC-9545): Roche
• Datopotamab Deruxtecan (Dato-DXd): AstraZeneca and Daiichi Sankyo
• Camizestrant (AZD9833): AstraZeneca
• LY3484356/Imlunestrant: Eli Lilly
• Lasofoxifene: Sermonix Pharmaceuticals
• Capivasertib: AstraZeneca
• Inavolisib: Roche/Genentech
• Enobosarm: Veru Pharma
• DB-1303: DualityBio/BioNtech
• SFX-01: Evgen Pharma
• Samuraciclib (CT-7001): Carrick Therapeutics
• Lerociclib: EQRx/G1 Therapeutics
• Eftilagimod Alpha (LAG-3lg/IMP321): Immutep
Discover more about therapies set to grab major Metastatic HR+/HER2-Ve Breast Cancer market share @ Metastatic HR+/HER2-Ve Breast Cancer Treatment Landscape
https://www.delveinsight.com/sample-request/metastatic-hr-positive-her2-negative-breast-cancer-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Metastatic HR+/HER2-Ve Breast Cancer Market Report
• Study Period: 2020-2034
• Coverage: APAC (India, China, South Korea, Taiwan, and Australia)
• Key Metastatic HR+/HER2-Ve Breast Cancer Companies: Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others
• Key Metastatic HR+/HER2-Ve Breast Cancer Therapies: KEYTRUDA (perbrolizumab), ARV-471 (vepdegestrant), OP1250 (palazestrant), Gedatolisib, Giredestrant (RG6171, GDC-9545), Datopotamab Deruxtecan (Dato-DXd), Camizestrant (AZD9833), LY3484356/Imlunestrant, Lasofoxifene, Capivasertib, Inavolisib, Enobosarm, DB-1303, SFX-01, Samuraciclib (CT-7001), Lerociclib, Eftilagimod Alpha (LAG-3lg/IMP321), and others
• Metastatic HR+/HER2-Ve Breast Cancer Therapeutic Assessment: Metastatic HR+/HER2-Ve Breast Cancer current marketed and Metastatic HR+/HER2-Ve Breast Cancer emerging therapies
• Metastatic HR+/HER2-Ve Breast Cancer Market Dynamics: Metastatic HR+/HER2-Ve Breast Cancer market drivers and Metastatic HR+/HER2-Ve Breast Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Metastatic HR+/HER2-Ve Breast Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic HR+/HER2-Ve Breast Cancer Market Access and Reimbursement
To know more about Metastatic HR+/HER2-Ve Breast Cancer companies working in the treatment market, visit @ Metastatic HR+/HER2-Ve Breast Cancer Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/metastatic-hr-positive-her2-negative-breast-cancer-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Metastatic HR+/HER2-Ve Breast Cancer Market Report Introduction
2. Executive Summary for Metastatic HR+/HER2-Ve Breast Cancer
3. SWOT analysis of Metastatic HR+/HER2-Ve Breast Cancer
4. Metastatic HR+/HER2-Ve Breast Cancer Patient Share (%) Overview at a Glance
5. Metastatic HR+/HER2-Ve Breast Cancer Market Overview at a Glance
6. Metastatic HR+/HER2-Ve Breast Cancer Disease Background and Overview
7. Metastatic HR+/HER2-Ve Breast Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Metastatic HR+/HER2-Ve Breast Cancer
9. Metastatic HR+/HER2-Ve Breast Cancer Current Treatment and Medical Practices
10. Metastatic HR+/HER2-Ve Breast Cancer Unmet Needs
11. Metastatic HR+/HER2-Ve Breast Cancer Emerging Therapies
12. Metastatic HR+/HER2-Ve Breast Cancer Market Outlook
13. Country-Wise Metastatic HR+/HER2-Ve Breast Cancer Market Analysis (2020-2034)
14. Metastatic HR+/HER2-Ve Breast Cancer Market Access and Reimbursement of Therapies
15. Metastatic HR+/HER2-Ve Breast Cancer Market Drivers
16. Metastatic HR+/HER2-Ve Breast Cancer Market Barriers
17. Metastatic HR+/HER2-Ve Breast Cancer Appendix
18. Metastatic HR+/HER2-Ve Breast Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Emesis Market: https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Continuous Renal Replacement Therapy Machines Market: https://www.delveinsight.com/report-store/continuous-renal-replacement-therapy-machines-market
• Burn Market: https://www.delveinsight.com/report-store/burns-market
• Menorrhalgia Market Size: https://www.delveinsight.com/report-store/menorrhalgia-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Diabetic Nephropathy Market: https://www.delveinsight.com/report-store/diabetic-nephropathy-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release APAC Metastatic HR+/HER2-Ve Breast Cancer Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight here
News-ID: 4110500 • Views: …
More Releases from DelveInsight Business Research
HPK1 Inhibitors Market Outlook 2034: Comprehensive 7MM Forecast, Emerging Pipeli …
DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know more about the HPK1 Inhibitor…
Hypersomnia Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Prog …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypersomnia pipeline constitutes 3+ key companies continuously working towards developing 4+ Hypersomnia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hypersomnia Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypersomnia Market.
The Hypersomnia Pipeline report embraces in-depth…
Diabetic Kidney Disease Pipeline 2026: Therapies Under Investigation, Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Kidney Disease pipeline constitutes key companies continuously working towards developing Diabetic Kidney Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Diabetic Kidney Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Kidney Disease Market.
…
Pompe Disease Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and K …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Pompe Disease pipeline constitutes 15+ key companies continuously working towards developing 20+ Pompe Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Pompe Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pompe Disease Market.
The Pompe Disease…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
